Key result
The DOAC era was associated with a significant increase in home treatment for DVT compared to the warfarin era, with no significant difference in adjusted risk of recurrent VTE.
Why the study?
Data were limited regarding temporal trends in the selection of home treatment and clinical outcomes among patients with DVT in routine clinical practice following the introduction of DOACs.
Does management in the DOAC era compared to the warfarin era increase the use of home treatment and improve clinical outcomes in patients with acute symptomatic DVT?
Cohort (n=3,722)
Yes
Does management in the DOAC era compared to the warfarin era increase the use of home treatment and improve clinical outcomes in patients with acute symptomatic DVT?
Answers are grounded in this paper and cite their sources.
The transition to the DOAC era for DVT management was associated with a significant increase in home treatment without compromising safety or efficacy outcomes compared to the warfarin era.
Background After the introduction of direct oral anticoagulants (DOAC) for venous thromboembolism (VTE), home treatment of deep vein thrombosis (DVT) has become more common. However, there have been limited data on the temporal trends in selection of home treatment and clinical outcomes of patients with DVT in the clinical practice, which could be important epidemiological data for understanding the unmet needs even in the DOAC era. Purpose This study aimed to explore temporal trends in management strategies and clinical outcomes of patients with DVT comparing the warfarin and DOAC eras, using a large-scale observational database. Methods We compared the 2 series of multicenter COMMAND VTE registries in Japan enrolling consecutive patients with acute symptomatic DVT: Registry-1: 1312 patients in the warfarin era (2010-2014) and Registry-2: 2410 patients in the DOAC era (2015-2020). We compared clinical characteristics, management strategies, and outcomes between the 2 groups. We also explored the factors associated with selecting home treatment in outpatients with DVT. Results Compared to Registry-1, patients in Registry-2 were older and more often had active cancer, chronic lung disease, transient risk factors for VTE, and autoimmune disease, and less often presented as proximal DVT or out-of-hospital onset. Among patients with out-of-hospital onset, the proportion of home treatment was significantly higher in Registry-2 than in Registry-1 (34% vs. 53%, P<0.001), although there was no significant difference in the median length of hospital stay between the 2 groups among hospitalized patients (15 vs. 15 days, P=0.36). The cumulative 5-year incidences of recurrent VTE (9.4% vs. 9.3%, log-rank P=0.38) and major bleeding (11.4% vs. 13.9%, log-rank P=0.30) were not significantly different between the 2 groups, whereas that of all-cause death was significantly higher in Registry-2 (28.4% vs. 33.2%, log-rank P=0.002). After adjusting for confounders, there were no significant differences in the risks of recurrent VTE (adjusted HR: 0.84, 95% CI: 0.64–1.11, P=0.23), major bleeding (adjusted HR: 1.01, 95% CI: 0.79–1.37, P=0.97), or all-cause death (adjusted HR: 1.01, 95% CI: 0.88–1.17, P=0.85). The multivariable logistic regression analysis revealed that absence of transient risk factors for VTE, proximal DVT, thrombocytopenia, and anemia, and time period of Registry-2 were independently associated with the selection of home treatment for outpatients with DVT. There was no significant difference in the adjusted risks of recurrent VTE, major bleeding, or all-cause mortality between patients with home treatment and hospitalized patients. Conclusions From warfarin to DOAC eras, the proportion of home treatment for patients with DVT increased significantly without any signals of worse outcomes comparing home treatment and in-hospital treatment, which suggested the potential usefulness of home treatment for most of patients with DVT in the DOAC era.
No takes yet. Share an insight, caveat, or question.
Ryusuke et al. (2025) conducted a cohort in Acute symptomatic deep vein thrombosis (DVT) (n=3,722). DOAC era (2015-2020) vs. Warfarin era (2010-2014) was evaluated on recurrent VTE (adjusted HR 0.84, 95% CI 0.64-1.11, p=0.23). The DOAC era was associated with a significant increase in home treatment for DVT compared to the warfarin era, with no significant difference in adjusted risk of recurrent VTE.
Synapse has enriched 10 related papers. Consider them for comparative context: